The Lingo over-the-counter CGM biosensor. [Image courtesy of Abbott]Abbott

Lingo非处方CGM生物传感器。[图片由雅培提供]雅培

(NYSE: ABT)

（纽约证券交易所：ABT）

+

+

today announced a major product launch, broadening the population that can utilize its continuous glucose monitoring (CGM) technology.

今天宣布推出一项主要产品，扩大了可以利用其连续血糖监测（CGM）技术的人群。

Our sister site, Drug Delivery Business News, reports that Abbott made its Lingo CGM system available without a prescription in the U.S.

我们的姊妹网站《药物输送商业新闻》报道，雅培在美国无需处方即可使用其术语CGM系统。

Lingo features a biosensor and mobile app designed for customers who want to improve their overall health and wellness. The company built Lingo on its FreeStyle Libre CGM technology platform.

Lingo拥有一个生物传感器和移动应用程序，专为希望改善整体健康状况的客户而设计。该公司在其FreeStyle Libre CGM技术平台上构建了Lingo。

Abbott received FDA clearance for Lingo and its Libre Rio over-the-counter (OTC) CGMs in June. The launch highlights the industry’s move beyond prescription CGMs, as Dexcom also launched its own Stelo OTC CGM last week.

6月，雅培获得了FDA对Lingo及其Libre Rio非处方药（OTC）CGM的批准。此次发布突显了该行业超越处方CGM的趋势，因为Dexcom上周也推出了自己的Stelo OTC CGM。

Lingo, a consumer biowearable, is available for consumers 18 years and older not on insulin. It tracks glucose in real time and provides personal insights and coaching. Abbott designed it to help people build healthy habits, retain their metabolism and improve their overall wellbeing.

Lingo是一种消费者生物穿戴设备，适用于18岁及以上的消费者，不使用胰岛素。它实时跟踪血糖，并提供个人见解和指导。雅培设计它是为了帮助人们建立健康的习惯，保持新陈代谢，改善整体健康。

Get the full story at our sister site, Drug Delivery Business News.

在我们的姊妹网站《药物输送商业新闻》上获取完整信息。